NICE approves non-invasive NHS tests to speed up endometriosis diagnosis

The National Institute for Health and Care Excellence (NICE) has issued new draft guidance that could fundamentally alter the diagnostic pathway for endometriosis within the National Health Service (NHS). By recommending two non-invasive tests for use in primary care, health officials aim to significantly reduce the current diagnostic delays that see patients waiting an average of nine years and four months for a formal diagnosis. For those from ethnically diverse communities, this delay can extend to 11 years.

The condition, which involves tissue similar to the lining of the womb growing in other pelvic organs, affects approximately one in 10 women of reproductive age. Dr. Anastasia Chalkidou, healthtech programme director at NICE, noted that the current wait times force patients to live with chronic pelvic pain that interferes with their daily lives, relationships, and work. The newly sanctioned tests are intended to provide GPs with additional tools to identify the condition earlier, facilitating faster access to appropriate treatment.

Media additions

New Diagnostic Technologies

NICE has green-lit the following two technologies for NHS use while further data on their long-term effectiveness is collected:

• Endotest: A laboratory-based saliva test that identifies the condition by analyzing the presence of specific biological markers known as microRNAs.
• EndoSure: A diagnostic tool that utilizes sensor pads placed on the abdomen to measure electrical signals within the gut. Patients are required to fast for six to eight hours before the 45-minute procedure.

According to reports, these tests are not intended as standalone diagnostic markers. Instead, they are designed to support clinical decision-making, particularly in cases where clinical examinations and existing imaging, such as ultrasounds, have proven inconclusive or were not previously utilized. While these methods are being introduced, NICE has indicated that a third technology, DotEndo, requires further research before it can be recommended for NHS funding.

Addressing the Diagnostic Gap

Historically, the definitive diagnosis of endometriosis has required a laparoscopy—a surgical procedure performed under general anaesthesia involving a small incision to examine the pelvis. For many patients, the path to this procedure is arduous; a survey of over 10,000 women conducted by the All-Party Parliamentary Group on endometriosis found that more than half had visited their GP more than 10 times before receiving a diagnosis.

The implementation of these tests is seen as a potential "game-changer" by medical professionals, including Dr. Gail Busby, a consultant gynaecologist at Manchester University NHS Foundation Trust. "An earlier diagnosis doesn’t just change one person’s life, it frees up appointments and surgical slots for everyone waiting for care," Dr. Busby stated. However, experts emphasize that technology alone is not a panacea. Emma Cox, chief executive of Endometriosis UK, noted that the rollout of these tests must be paired with education of GPs and practice nurses to ensure prompt access to those that need them, and an end to pain and symptoms not being recognised.

Primary Care Perspectives

Research published in the Pmc journal indicates that GPs often navigate a hierarchy of symptoms to exclude "red flags" before considering a diagnosis like endometriosis. Because symptoms are frequently non-specific and overlap with other issues, GPs must balance the need for early investigation against the risks of invasive procedures and the potential anxiety caused by premature diagnostic labels.

GPs have expressed that they often rely on trials of hormonal treatments to manage symptoms. The new guidance acknowledges this reality by positioning the tests as tools to inform "next steps in diagnosis and care" rather than replacing professional clinical judgment.

What to Watch Next

As the NHS begins the pilot and clinical study phases for these technologies, the following factors will be critical in determining their long-term success:

• Evidence Gathering: The NHS will continue to gather evidence on how well these tests work.
• Integration: How these tests will shift the current reliance on transvaginal ultrasounds and whether they will effectively reduce the burden on gynaecology departments.

For patients, the focus remains on ensuring that these tools serve as an "open door" to further care, rather than a final destination in a healthcare journey that has historically been characterized by long silences and insufficient support.